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Abstract: The efficient organocatalytic synthesis of heterocyclic systems of biological relevance is
a subject of growing interest. We have found that the pyrrolidine/benzoic acid-catalyzed reaction
of α-substituted propenals such as methacrolein, 2-benzylpropenal and 2-(n-hexyl)propenal with
activated hydrazines takes place in very good yields (83%–99.6%) under very mild conditions to
afford 4-substituted pyrazolidin-3-ols (as diastereomer mixtures); subsequent oxidation with PCC
affords the corresponding-4-substituted-3-pyrazolidinones in essentially quantitative yields. In a
similar way, 4-substituted isoxazolidinones are obtained with N-Cbz-hydroxylamine as a reagent.
The use of chiral diarylprolinol trimethylsilyl ethers as catalysts allows the synthesis of several of these
compounds in optically active form, in some cases with excellent enantioselectivity (up to 96:4 er).
A preliminary evaluation of the biological activity shows that some of these compounds exhibit
interesting antibacterial and antifungal activities.
Keywords: asymmetric catalysis; isoxazolidinones; pyrazolidinones; organocatalysis; hydrazines;
hydroxylamines; enals
1. Introduction
The pyrazolidinone (pyrazolidin-3-one) moiety is an important structural motif that can be
found both in natural products and in synthetic compounds with interesting pharmacological
activity (analgesic, antibiotic, anticonvulsant, and with inhibitory cyclooxygenase, lipoxygenase, and
γ-aminobutyrate transferase activity, among others) [1–10]. On the other hand, the selective oxidation
of pyrazolidinones affords the corresponding pyrazolones (pyrazol-5-ones), a class of compounds
that also exhibits very relevant pharmacological properties [11–18]. Figure 1 shows structures of some
biologically active pyrazolidinones and pyrazolones.
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excellent yields and good diastereoselectivities [26], so that we set out to investigate if the secondary 
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We began our research by examining the pyrrolidine-catalyzed addition/cyclization of cyclopentene-
1-carboxaldehyde (1) with 1-Boc-2-(4-nitrobenzenesulfonyl)hydrazine (2a) [20] using benzoic acid as 
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It is therefore not surprising that efficient and selective syntheses of pyrazolidinone derivatives
have been actively pursued [19]. Recently, organocatalytic approaches to these compounds, based either
on the amine-catalyzed [20,21] or on the carbene-catalyzed [22] reaction of α,β-unsaturated aldehydes
with hydrazine derivatives and subsequent oxidation of the intermediate pyrazolidinols, have been
described, enabling their preparation in optically active form [23–25]. Although these approaches are
highly interesting, all of them suffer from the common limitation that they have been applied only to
β-substituted enals, so that they can exclusively lead to 5-substituted-3-pyrazolidinones.
In the course of our studies on the organocatalytic synthesis of α,β-disubstituted-β-amino
acids we had found that the pyrrolidine-promoted aza-Michael addition/cyclization of N-protected
hydroxylamines to acyclic α,β-unsaturated, α,β-disubstituted enals took place in several instances with
excellent yields and good diastereoselectivities [26], so that we set out to investigate if the secondary
amine-catalyzed reaction of these branched enals with substituted hydrazines, followed by oxidation of
the resulting pyrazolidin-3-ols, would provide a general route to 4,5-disubstituted-3-pyrazolidinones
(Scheme 1).
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2. Results and Discussion
2.1. Organocatalytic Synthesis of 4-Substituted Pyrazolidinones and Isoxazolidinones
We began our research by examining the pyrrolidine-catalyzed addition/cyclization of
cyclopentene-1-carboxaldehyde (1) with 1-Boc-2-(4-nitrobenzenesulfonyl)hydrazine (2a) [20] using
benzoic acid as a co-catalyst. After some experiments, we found that by using 40 mol % of both
pyrrolidine and benzoic acid the expected bicyclic pyrazolidin-3-ol 3 was obtained in excellent yield
(87% isolated yield after chromatographic purification) and as a single isomer (dr > 30:1), after three
days in toluene at room temperature (r.t.) (Scheme 2).
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Next, we tried the same reaction conditions with acyclic α,β-substituted enals. While the reaction
with tiglic aldeyhyde ((E)-2-methylbutenal, 4) led to the formation of the pyrazolidinol 5 (76% yield,
6:1 dr), we found that (E)-2-methyl-3-phenylbutenal 6 was completely unreactive, no product being
detected after 7 days of stirring at r.t. (Scheme 3).
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Contrary to w at e ad observed for the corresponding is xazolidinols [26], attempted oxidation
of both 3 and 5, eith r with pyridinium chlor chromate (PCC) or with pyridinium dichromate (PDC),
failed to cleanl give the desired pyrazol dinones, o we decided to reduce th steric hindrance of the
interm diate pyrazolidinols by suppressing the β-subst tuent in he starting enal.
We were pleased to find that the pyrrolidine/benzoic acid-cat yzed reaction of the α-substitut d
en ls methacrolein (7a), 2-benz lpropenal (7b), or 2-(n-hexyl)pr penal (7c) with the ctivated
hydrazines 2a and 1,2-bis(p-toluenesulfonyl)hydrazin (2b) took place in very good yields (83%–99.6%),
afford ng the 4-substituted pyraz lidin-3-ols 8aa–8bc as diastereomer mixtures; without further
purifica on, oxidation with PCC was performed to afford the corresponding-4-substituted-3-
pyrazolidinones 9aa–9bc in essentially quantitative yields (Scheme 4 and Table 1).
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Table 1. Pyrrolidine-catalyzed synthesis of pyrazolidin-3-ols 8aa–8bc from α-substituted enals 7a–7c
and hydrazines 2a and 2b, and oxidation to the corresponding pyrazolidin-3-ones 9aa–9bc.
Entry Reactants R X Y Pyrazolidinol Yield 1 Reaction Time (Day) dr 2 Pyrazolidinone Yield 1
1 7a, 2a Me Ns Boc 8aa 93% 4 4:1 9aa 94%
2 7b, 2a PhCH2 Ns Boc 8ab 83% 2 >20:1 9ab 98%
3 7c, 2a n-Hexyl Ns Boc 8ac 99.6% 2 5:1 9ac 99%
4 7a, 2b Me Ts Ts 8ba 88% 2 8:1 9ba 98%
5 7b, 2b PhCH2 Ts Ts 8bb 85% 2 9:1 9bb 97%
6 7c, 2b n-Hexyl Ts Ts 8bc 98% 2 10:1 9bc 98%
1 Yield of isolated product after chromatographic purification; 2 By 1H-NMR.
As it can be seen, the aza-Michael addition/cyclization step took place in excellent yield
and with high diastereoselectivity, irrespective of the nature of the hydrazine (2a or 2b) and of
the acrolein substituent (methyl, benzyl, or n-hexyl). It should be noted however that when the
more hindered α-isopropyl acrylaldehyde (3-methyl-2-methylenebutyraldehyde (7d)) was used
under the same conditions, no reaction with hydrazine 2a was observed after 7 days at rt. In our
hands, N,N’-bis(tert-butoxycarbonyl)hydrazine (2c), reported to give good yields of pyrazolidin-3-ols
upon pyrrolidine-catalyzed reaction with cinnamaldehyde derivatives [21], failed to react with the
α-substituted enals 1, 4, and 7a–7d.
In the light of these results, we explored the possible use of the α-substituted acroleins 7 as starting
materials for the synthesis of 4-substituted isoxazolidin-5-ones, potentially interesting compounds
both from the biological point of view and as advanced intermediates towards α-substituted-β-amino
acids [26], by the amine-catalyzed reaction with a suitable protected hydroxylamine. To our satisfaction,
we found that in fact α-substituted acroleins 7, with the sole exception of the isopropyl derivative
7d, reacted smoothly with N-Cbz-hydroxylamine 10 (Cbz = benzyloxycarbonyl) to afford the
isoxazolidinols 11 in good yields (78%–83% isolated yields) as diastereomer mixtures. Subsequent
oxidation of these compounds with PCC took place uneventfully, providing the target 4-substituted
isoxazolidin-5-ones 12 (Scheme 5 and Table 2).
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that the use of chiral diarylprolinol-silyl ethers as catalysts led to high enantioselectivities in the  
aza-Michael/cyclization reactions of β-substituted [20,27,28] and of α,β-disubstituted [26] enals with 
hydroxylamines or hydrazines. However, α-branched vinyl carbonyls remain a very challenging 
substrate for this type of reaction and only one successful example of aminocatalytic asymmetric  
aza-Michael addition to α-substituted vinyl ketones has been reported so far [29,30]. Bearing these 
precedents in mind, we proceeded to examine the performance of the Jørgensen-Hayashi catalysts 13 
and 14 (Figure 2) in the reaction between aldehydes 7a–7c and hydrazines 2a and 2b (Table 3), using 
Scheme 5. Organocatalytic synthesis of isoxazolidin-5-ones from α-substituted enals.
Table 2. Pyrrolidine-catalyzed synthesis of isoxazolidin-5-ols 11a–11c from α-substituted enals 7a–7c
and N-Cbz-hydroxylamine 10, and oxidation to the corresponding isoxazolidin-5-ones 12a–12c.
Entry Reactants R Isoxazolidinol Yield 1 dr 2 Isoxazolidinone Yield 1
1 7a, 10 Me 11a 83% 2:1 12a 98%
2 7b, 10 PhCH2 11b 79% 3:1 12b 99
3 7c, 10 n-Hexyl 11c 78% 3:1 2c 87%
1 Yield of isolated product after chromatographic purification. 2 By 1H-NMR.
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Previous studies from our group [26] and those of Córdova [27,28] and Vicario [20] had shown
that the use of chiral diarylprolinol-silyl ethers as catalysts led to high enantioselectivities in the
aza-Michael/cyclization reactions of β-substituted [20,27,28] and of α,β-disubstituted [26] enals with
hydroxylamines or hydrazines. However, α-branched vinyl carbonyls remain a very challenging
substrate for this type of reaction and only one successful example of aminocatalytic asymmetric
aza-Michael addition to α-substituted vinyl ketones has been reported so far [29,30]. Bearing these
precedents in mind, we proceeded to examine the performance of the Jørgensen-Hayashi catalysts
13 and 14 (Figure 2) in the reaction between aldehydes 7a–7c and hydrazines 2a and 2b (Table 3),
using a 20 mol % of the catalyst together with a 20 mol % of benzoic acid co-catalyst in toluene at r.t.
(typical reaction time 3 days). The stereoisomeric mixture of pyrazolidinols 8 was then submitted to
oxidation with PCC as before, and the enantiomeric purity of the corresponding pyrazolidinones 9
was determined by chiral HPLC analysis. After 7 days of stirring at rt, no product was observed in the
attempted reactions of aldehyde 7c with hydrazine 2a, either when using 13 or 14 as catalysts. On the
other hand, we could not find satisfactory HPLC conditions for the separation of the enantiomers
of 9bb, so that the enantioselective catalysis for the reaction of aldehyde 7b with hydrazine 2b was
not attempted.
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Figure 2. Jørgensen-Hayashi catalysts 13 ((S)-diphenylprolinol tri ethylsilyl ether) and 14
((S)-bis(3,5-trifluoro ethylphenyl)prolinol tri ethylsilyl ether) used in the enantioselective synthesis
of pyrazolidinones 9.
Table 3. Enantioselective synthesis of pyrazolidin-3-ones 9.
Entry Reactants Catalyst Pyrazolidinol Yield 1 dr 2 Pyrazolidinone Yield 1 er 3
1 7a, 2a 13 8aa 82% 4:1 9aa 87% 50:50
2 7a, 2a 14 8aa 99% 3:1 9aa 94% 90:10
3 7b, 2a 13 8ab 77% >20:1 9ab 98% 44:56
4 7b, 2a 14 8ab 98 >20:1 9 :
5 7b, 2b 13 8 b 85 9:1 9 97 - 4
6 7b, 2b 14 8bb 85% 9:1 9bb 97% - 4
7 7a, 2b 13 8ba 84% 8:1 9ba 98% 96:4
8 7a, 2b 14 8ba 0% 5 9ba - -
9 7c, 2b 13 8bc 93% 10:1 9bc 98% 78:22
10 7c, 2b 14 8bc 77 10:1 9 50:50
1 Yield of isolated product after chromatographic purification; 2 By 1H-NMR; 3 By chiral HPLC analysis (See the
Supplementary Materials for details); 4 No satisfactory conditions for the HPLC analysis of this compound
could be found; 5 No reaction was observed after 7 days.
As it can be seen in Table 3, the enantioselectivity of the reaction depends strongly both in the
nature of the reactants and of the catalyst. The highest enantiomeric purities were obtained for the
less hindered methyl-substituted enal 7a, either with hydrazine 2a (entry 2, 90:10 er, catalyst 14) or
with hydrazine 2b (entry 7, 96:4 er, catalyst 13). In any case, these preliminary results demonstrate
for the first time the feasibility of the asymmetric synthesis of 4-substituted-3-pyrazolidinones by the
organocatalytic aza-Michael/cyclization of activated hydrazines to α-substituted acroleines.
A simplified mechanistic proposal for the formation of enantiomerically enriched 4-substituted
pyrazolidinols 8aa–8ac is depicted in Scheme 6. While in the formation of the first carbon-nitrogen
bond by the aza-Michael reaction of the chiral iminium intermediate A (formed from the α-substituted
Molecules 2016, 21, 1655 6 of 16
enal 7a–c and the chiral pyrrolidine catalyst 13 or 14) with the hydrazine 2a no new chiral center
is formed, the protonation of the intermediate enamine B can take place on the two diastereotopic
faces of the C–C double bond. When using the trifluoromethyl-substituted catalyst 14, we assume
(based on our previous studies on the asymmetric organocatalytic synthesis of isoxazolidines) [26]
that when R = Me protonation will take place under kinetic control from the face opposite to the bulky
pyrrolidine substituent, leading to the second iminium intermediate C as the major diastereomer.
Fast, irreversible hydrolysis and cyclization of this intermediate would predominantly give the (4R)
enantiomer of 8aa. When the steric bulk of the R substituent is increased (7b or 7c), the formation of the
diastereomeric iminium ion C’ will be relatively favoured (in this intermediate the steric interactions
of the α-substituent R with the pyrrolidine substituent are minimized), resulting of the competitive
formation of the (4S) enantiomer of the pyrazolidinol 8ab or 8ac.
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When the asymmetric synthesis of isoxazolidinones 12a–12c was attempted by means of the use
of the chiral catalysts 13 and 14 in the reactions between enals 7a–7c and N-Cbz-hydroxylamine 10,
the results were much less satisfactory, since after oxidation of the intermediate isoxazolidinols 11a–11c
to the corresponding isoxazolidinones 12, we were not able to find suitable HPLC conditions for the
determination of the enantiomeric purity of 12a; on the other hand, 12b was obtained in essentially
racemic form with both catalysts, and scalemic 12c could be prepared but only in low enantiomeric
purity (57:43 er) when using 14 as the chiral catalyst (see details in the Experimental Section).
2.2. Primary Antimicrobial Screening
Finally, and in the framework of the Community for Open Antimicrobial Drug Discovery
(CO-ADD) program [31], the new heterocyclic systems synthesized by us (both in racemic and when
possible in enantiomerically enriched form) were submitted to a primary antimicrobial screening
study by whole cell growth inhibition assays. The inhibition of growth was measured against five
bacteria: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and
Staphylococcus aureus, and two fungi: Candida albicans and Cryptococcus neoformans. The results of the
study are summarized in Table 4, which shows the active compounds found for each microbial strain.
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Table 4. Active compounds 1 in the primary antimicrobial screening (bacterial and fungal).
Entry S. aureus E. coli K. pneumoniae A. baumannii P. aeruginosa C. albicans C. neoformans
1 - - - - - 12b -
2 8aa (rac) - - - - - -
3 8aa (90:10 er) - - - - - -
4 - - - - - - 12a
5 - - - - 11c -
1 Compounds showing inhibition > 80% and Z-score > 2.5 in two replicate experiments, at a concentration of
32 µg/mL (water/DMSO).
Among the samples tested, five showed antimicrobial activity and have been selected for
hit confirmation. It is worth noting that antifungal activity was found only for isoxazolidinones
(12a and 12b) and for isoxazolidinol 11c, and that the pyrazolidinol 8aa, both in racemic and in
enantiomerically enriched form, was active against Staphylococcus aureus. The fact that neither
the corresponding pyrazolidinone 9aa nor the 4-methyl-1,2-bis-(p-toluenesulfonyl)pyrazolidin-3-ol
8ba show any growth inhibition for the same bacterial strain strongly suggests that 4-methyl-1-
(4-nitrobenzenesulfonyl)-4,5-dihydro-1H-pyrazole, resulting from acid-catalyzed deprotection/
dehydration of 8aa [20], could be the biologically active species.
3. Experimental Section
3.1. General Information
Reactions were generally performed at room temperature, either in round-bottomed flasks or
in loosely stoppered glass vials, with magnetic stirring and open to the air. Commercially available
reagents, catalysts, and solvents were used as received with the exception of dichloromethane, which
was distilled from calcium hydride under nitrogen. Aldehydes 1 [32] and 7b–7d [33,34] were prepared
according to literature procedures. Yields refer to products isolated after chromatographic purification.
Reactions were monitored both by 1H-NMR and by thin-layer chromatography, carried out on silica
gel plates Merck 60 F254 (Sigma-Aldrich Química SL, Madrid, Spain), and compounds were visualized
by irradiation with UV light and/or treatment with a solution of KMnO4 as developing agent followed
by heating. Flash column chromatography was performed using silica gel Merck 60 (particle size:
0.040–0.063 mm). 1H (400 MHz) and 13C (100.6 MHz) NMR spectra were recorded with a Mercury
400 spectrometer (Varian Inc., Palo Alto, CA, USA). Chemical shifts (δ) are given in ppm relative to
tetramethylsilane (TMS), and coupling constants (J) are given in Hz. The spectra were recorded in
CDCl3 as solvent at room temperature. TMS served as an internal standard (δ = 0.00 ppm) for 1H-NMR
spectra, and CDCl3 (δ = 77.0 ppm) for 13C-NMR spectra. Data are reported as follows: s, singlet;
d, doublet; t, triplet; q, quartet; m, multiplet; br, broad signal. Where appropriate, 2D techniques
(COSY, NOESY) were also used to assist in structure elucidation. High-resolution mass spectra
(HRMS) were recorded with a MicrOTOF spectrometer (Bruker, Billerica, MA, USA) by the Unitat
d’Espectrometria de Masses, CCiT-UB. Specific rotations were determined at room temperature with a
241 MC polarimeter (Perkin-Elmer, Waltham, MA, USA). Chiral HPLC analyses were performed with
a LC Series 20 apparatus (Shimadzu Corp., Kyoto, Japan) with an M20 diode array UV/Vis detector,
using Chiralpak® IC, IA and IB columns (Daicel Corporation, Tokio-Osaka, Japan). The homogeneity of
the peaks corresponding to the two enantiomers of the product was thoroughly checked by comparison
of the UV spectra.
3.2. General Procedures for the Preparation of Pyrazolidines
3.2.1. Racemic Pyrazolidinols from Enals and Hydrazines
An ordinary glass vial equipped with a magnetic stirring bar was charged with pyrrolidine
(1.42 mL, 14 mg, 0.20 mmol, 40 mol %), PhCOOH (24 mg, 0.20 mmol, 40 mol %) and toluene (2 mL).
The hydrazine 2a or 2b (0.50 mmol, 1 eq) and the α,β-unsaturated aldehyde (1.0 mmol, 2 eq) were
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added sequentially. Stirring was maintained at room temperature until the reaction was complete
(TLC and or 1H-NMR monitoring, 24 h–4 days) and the crude reaction mixture was diluted with 10 mL
of ethyl acetate. The organic phase was washed first with 10% w/w aqueous sodium bicarbonate
solution (10 mL), then with brine (10 mL), and dried over MgSO4. Filtration and evaporation of
solvents under reduced pressure afforded the crude reaction product that was purified by column
chromatography (silica gel; hexane/ethyl acetate mixtures of increasing polarity) to afford the
intermediate pyrazolidinol as a diastereomer mixture.
3.2.2. Asymmetric Synthesis of Pyrazolidinols from Enals and Hydrazines
An ordinary glass vial equipped with a magnetic stirring bar was charged with the chiral prolinol
silyl ether 13 or 14 (0.05 mmol, 20 mol %), PhCOOH (6 mg, 0.05 mmol, 20 mol %) and toluene (1 mL).
The hydrazine 2a or 2b (0.24 mmol, 1 eq) and the α,β-unsaturated aldehyde (0.48 mmol, 2 eq) were
added sequentially. The stirring was maintained at room temperature until the reaction was complete
(TLC and or 1H-NMR monitoring, 3–6 days) and the crude reaction mixture was diluted with 10 mL of
ethyl acetate. The organic phase was washed first with 10% w/w aqueous sodium bicarbonate solution
(10 mL), then with brine (10 mL), and dried over MgSO4. Filtration and evaporation of solvents under
reduced pressure afforded the crude reaction product that was purified by column chromatography
(silica gel; hexane/ethyl acetate mixtures of increasing polarity) to afford the intermediate pyrazolidinol
as a diastereomer mixture.
3.2.3. Pyrazolidinones by Oxidation of Pyrazolidinols
The pyrazolidinol diastereomer mixture (0.15 mmol) and pyridinium chlorochromate PCC
(158 mg, 0.73 mmol, 5 eq) were added sequentially to a stirred suspension of activated 4 Å molecular
sieves (300 mg) in anhydrous dichloromethane (2 mL), and the reaction mixture was stirred at room
temperature until completion (24–48 h). After the addition of diethyl ether (10 mL) to precipitate the
chromium salts, the solution was decanted and filtered through a short pad of Celite® eluting with a
1:10 mixture of ethyl acetate and diethyl ether). After removal of the solvents in vacuo, the reaction
product was purified by column chromatography (silica gel, hexane/ethyl acetate mixtures) to give
the desired pyrazolidinone.
3.3. General Procedures for the Preparation of Isoxazolidines
3.3.1. Racemic Isoxazolidinols from Enals and Hydroxylamine 10
Pyrrolidine (from a 10 mg/mL solution in toluene; 1.48 mL, 0.21 mmol, 40 mol %) and
N-Cbz-hydroxylamine 10 (87 mg, 0.52 mmol, 1 eq) were added sequentially to a magnetically stirred
solution of the α,β-unsaturated aldehyde 7a, 7b, or 7c (1.04 mmol, 2 eq) in toluene (2 mL), and the
resulting solution was stirred at room temperature. The progress of the reaction was monitored both
by 1H-NMR spectroscopy and by TLC. When the starting hydroxylamine 10 was not detected (2 days),
toluene and pyrrolidine were removed in vacuo, and the crude residue was directly purified by column
chromatography (silica gel; hexane/ethyl acetate mixtures) to give the corresponding isoxazolidinol as
a diastereomer mixture.
3.3.2. Asymmetric Synthesis of Isoxazolidinols from Enals and Hydroxylamine 10
The chiral prolinol silyl ether 13 or 14 (0.104 mmol, 20 mol %) and N-Cbz-hydroxylamine 10 (87 mg,
0.52 mmol, 1 eq) were added sequentially to a magnetically stirred solution of the α,β-unsaturated
aldehyde 7a, 7b, or 7c (1.04 mmol, 2 eq) in toluene (2 mL), and the resulting solution was stirred at
room temperature. The progress of the reaction was monitored both by 1H-NMR spectroscopy and by
TLC. When the starting hydroxylamine 10 was not detected (3 days), toluene was removed in vacuo,
and the crude residue was directly purified by column chromatography (silica gel; hexane/ethyl
acetate mixtures) to give the corresponding isoxazolidinol as a diastereomer mixture.
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3.3.3. Isoxazolidinones by Oxidation of Isoxazolidinols
The isoxazolidinol diastereomer mixture (0.126 mmol) and pyridinium chlorochromate PCC
(82 mg, 0.38 mmol, 5 eq) were added sequentially to a stirred suspension of activated 4Å molecular
sieves (150 mg) in anhydrous dichloromethane (2 mL), and the reaction mixture was stirred overnight
at room temperature. After the addition of diethyl ether (5 mL) to precipitate the chromium salts,
the solution was decanted and filtered through a short pad of Celite® eluting with a 4:1 mixture of
hexane and ethyl acetate. After removal of the solvents in vacuo, the reaction product was purified by
column chromatography (silica gel, hexane/ethyl acetate mixtures) to give the desired isoxazolidinone.
3.4. Characterization of the Products
tert-Butyl (3RS,3aRS,6aSR)-3-hydroxy-1-((4-nitrophenyl)sulfonyl)hexahydrocyclopenta[c]pyrazole-2(1H)-
carboxylate, 3. Obtained in 87% yield (450 mg, 1.09 mmol) according to Procedure 3.2.1. Colorless solid,
m.p. 83–85 ◦C (from 1:9 chloroform/hexanes). 1H-NMR (CDCl3): δ = 1.24 (s, 9H), 1.47–1.54 (m, 3H),
1.67–1.75 (m, 1H), 1.77–1.83 (m, 1H), 1.86–1.95 (m, 1H), 2.72–2.77 (m, 1H), 3.38 (br d, 1H, OH), 4.73–4.78
(m, 1H), 5.42 (m, 1H), 8.11 (d, J = 8.0 Hz, 2H), 8.29 (d, J = 8.0 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 24.5,
27.8, 30.5, 33.7, 53.6, 62.2, 65.5, 83.0, 91.9, 123.7, 131.1, 141.8, 150.7 ppm. HRMS (ESI): Calculated for
C17H27N4O7S [M + NH4]+ = 431.1595; found, 431.1592.
tert-Butyl 3,4-trans-5-hydroxy-3,4-dimethyl-2-((4-nitrophenyl)sulfonyl)-pyrazolidine-1-carboxylate, 5. Obtained
as a 6:1 diastereomer mixture in 76% yield (380 mg, 0.95 mmol) according to Procedure 3.2.1. Colorless
solid, m.p. 71–73 ◦C (major isomer, 1:9 chloroform/hexanes). 1H-NMR (CDCl3): δ = 1.00 (d, J = 7.0 Hz,
3H), 1.24 (s, 9H), 1.36 (d, J = 7.0 Hz, 3H), 1.80–1.87 (m, 1H), 2.86 (br d, 1H, OH), 3.72–3.79 (m, 1H),
5.46–5.48 (m, 1H), 8.07 (d, J = 8.0 Hz, 2H), 8.28 (d, J = 8.0 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 11.1,
20.7, 27.81, 27.83, 47.4, 62.2, 83.2, 86.6, 123.6, 130.9, 141.8, 150.6, 154.7 ppm. HRMS (ESI): Calculated for
C16H24N3O7S [M + H]+ = 402.1337; found, 402.1340.
tert-Butyl 5-hydroxy-4-methyl-2-((4-nitrophenyl)sulfonyl)-pyrazolidine-1-carboxylate, 8aa. The racemic
compound was obtained as a 4:1 diastereomer mixture in 93% yield (180 mg, 0.47 mmol) according to
Procedure 3.2.1. Colorless solid, m.p. 111–114 ◦C (major isomer, 1:9 chloroform/hexanes). 1H-NMR
(CDCl3): δ = 1.09 (d, J = 7.0 Hz, 3H), 1.35 (s, 9H), 2.25–2.30 (m, 1H), 3.03–3.09 (m, 1H), 3.22 (br d, 1H,
OH), 3.29–3.36 (m, 1H), 3.83–3.87 (m, 1H), 5.47 (m, 1H), 8.12 (d, J = 8.0 Hz, 2H), 8.34 (d, J = 8.0 Hz,
2H) ppm. 13C-NMR (CDCl3): δ = 15.0, 27.9, 43.0, 55.3, 83.2, 91.9, 123.9, 131.0, 141.8, 150.8, 154.5 ppm.
HRMS (ESI): Calculated for C15H21N3NaO7S [M + Na]+ = 410.0992; found, 410.1000. When using 14
as a catalyst and following Procedure 3.2.2, scalemic 8aa was obtained in 98.6% yield (3:1 diastereomer
mixture). Colorless solid, m.p. = 135–137 ◦C (major isomer, 1:9 chloroform/hexanes).
(−)-tert-Butyl 4-methyl-2-((4-nitrophenyl)sulfonyl)-pyrazolidin-5-one-1-carboxylate, 9aa. Oxidation of 8aa
obtained by catalyst 14 gave (−)-9aa (90:10 er) in 94% yield (101 mg, 0.26 mmol) according to
Procedure 3.2.3. Colorless solid, m.p. 131–134 ◦C (from 1:9 chloroform/hexanes). 1H-NMR (CDCl3):
δ = 1.16 (d, J = 7.0 Hz, 3H), 1.47 (s, 9H), 2.54–2.64 (m, 1H), 3.38–3.45 (m, 1H), 4.40–4.45 (m, 1H), 8.18
(d, J = 8.0 Hz, 2H), 8.41 (d, J = 8.0 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 13.4, 27.7, 36.8, 53.7, 85.6, 124.4,
130.7, 141.3, 151.4, 173.4 ppm. HRMS (ESI): Calculated for C15H19N3NaO7S [M + Na]+ = 408.0836;
found, 408.0847. [α]25D = −56.0 (1.23, DCM). Conditions for the HPLC analysis: Chiralpak® IC column,
90:10 hexane/2-propanol, 1 µL/min, 25 ◦C, λ = 254 nm. tR (major enant.) = 58.1 min, tR (minor enant.)
= 84.4 min.
tert-Butyl 4-benzyl-5-hydroxy-2-((4-nitrophenyl)sulfonyl)-pyrazolidine-1-carboxylate, 8ab. The racemic
compound was obtained in 83% yield (165 mg, 0.36 mmol, >20:1 dr) according to procedure 3.2.1.
Colorless solid, m.p. 122–126 ◦C (major isomer, recrystallized from 1:2:7 dichloromethane/
chloroform/hexanes). 1H-NMR (CDCl3): δ = 1.36 (s, 9H), 2.53–2.58 (m, 2H), 3.14–3.19 (m, 1H),
3.24 (br d, 1H, OH), 4.01–4.06 (m, 1H), 5.39–5.41 (m, 1H), 7.09 (d, J = 7.8 Hz, 2H), 7.20–7.33 (m, 3H),
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8.13 (d, J = 8.0 Hz, 2H), 8.34 (d, J = 8.0 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 27.9, 36.7, 50.1, 53.7,
83.3, 89.9, 123.8, 126.9, 128.4, 128.8, 131.0, 137.8, 141.7, 150.8, 154.3 ppm. HRMS (ESI): Calculated
for C21H25N3NaO7S [M + Na]+ = 486.1305; found, 486.1298. When using 13 as a catalyst and
following Procedure 3.2.2, scalemic 8ab was obtained in 77% yield. Colorless solid, m.p. = 132–136 ◦C
(major isomer, 1:2:7 dichloromethane/chloroform/hexanes).
(−)-tert-Butyl 4-benzyl-2-((4-nitrophenyl)sulfonyl)-pyrazolidin-5-one-1-carboxylate, 9ab. Oxidation of 8ab
obtained by catalyst 13 gave (−)-9ab (44:56 er) in 98% yield (108 mg, 0.23 mmol) according to
Procedure 3.2.3. Colorless solid, m.p. 115–118 ◦C (recrystallized from 1:2:7 dichloromethane/
chloroform/hexanes). 1H-NMR (CDCl3): δ = 1.46 (s, 9H), 2.61–2.67 (m, 1H), 2.86–2.92 (m, 1H),
3.17–3.21 (m, 1H), 3.46–3.52 (m, 1H), 4.16–4.21 (m, 1H), 7.07 (d, J = 6.7 Hz, 2H), 7.25–7.32 (m, 3H), 8.13
(d, J = 7.8 Hz, 2H), 8.37 (d, J = 7.8 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 27.7, 34.8, 43.6, 51.7, 85.7, 124.3,
127.2, 128.5, 130.7, 136.7, 141.2, 147.5, 151.4, 172.1 ppm. HRMS (ESI): Calculated for C42H50N7O14S2
[2M + NH4]+ = 940.2852; found, 940.2847. [α]25D =−11.4 (1.19, DCM). Conditions for the HPLC analysis:
Chiralpak® IC column, 90:10 hexane/2-propanol, 1 µL/min, 25 ◦C, λ = 254 nm. tR (minor enant.) =
62.4 min, tR (major enant.) = 73.2 min.
tert-Butyl 4-hexyl-5-hydroxy-2-((4-nitrophenyl)sulfonyl)-pyrazolidine-1-carboxylate, 8ac. Obtained in 99.6%
yield as a diastereoisomer mixture (227 mg, 1.00 mmol, 5:1 dr) according to Procedure 3.2.1. Colorless
solid, m.p. 83–85 ◦C. 1H-NMR (CDCl3, major isomer): δ = 0.86 (t, J = 7Hz, 3H), 1.25–1.32 (m, 8H), 1.33
(s, 9H), 1.49–1.56 (m, 2H), 2.15–2.19 (m, 1H), 3.01–3.07 (m, 1H), 3.25 (br d, 1H, OH), 4.19–4.24 (m, 1H),
5.25–5.28 (m, 1H), 8.17 (d, J = 8.0 Hz, 2H), 8.36 (d, J = 8.0 Hz, 2H) ppm. HRMS (ESI): Calculated for
C40H62N6NaO14S2 [2M + Na]+ = 937.3658; found, 937.3654.
tert-Butyl 4-hexyl-2-((4-nitrophenyl)sulfonyl)-pyrazolidin-5-one-1-carboxylate, 9ac. Obtained in 99% yield
(150 mg, 0.33 mmol) according to Procedure 3.2.3. Colorless solid, m.p. 123–126 ◦C. 1H-NMR (CDCl3):
δ = 0.87 (t, J = 6.5 Hz, 3H), 1.24–1.30 (m, 9H), 1.47 (s, 9H), 1.78–1.83 (m, 1H), 2.40–2.47 (m, 1H), 3.42–3.49
(m, 1H), 4.37–4.42 (m, 1H), 8.19 (d, J = 7.8 Hz, 2H), 8.42 (d, J = 7.8 Hz, 2H) ppm. 13C-NMR (CDCl3):
δ = 13.9, 22.5, 26.8, 27.7, 28.8, 29.1, 31.4, 41.8, 52.6, 124.4, 130.7, 141.3, 147.7, 151.3, 172.9 ppm. HRMS
(ESI): Calculated for C20H29N3NaO7S [M + Na]+ = 478.1618; found, 478.1627.
4-Methyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-ol, 8ba. The racemic compound was obtained as a 8:1
diastereomer mixture in 88% yield (75 mg, 0.18 mmol) according to Procedure 3.2.1. Yellow solid,
m.p. 131–134 ◦C. 1H-NMR (CDCl3, major isomer): δ = 0.86 (d, J = 7.0 Hz, 3H), 2.17–2.25 (m, 2H), 2.45
(s, 3H), 2.46 (s, 3H), 3.33–3.40 (m, 1H), 4.04–4.11 (m, 1H), 5.21–5.22 (m, 1H), 7.29–7.33 (m, 4H), 7.70
(d, J = 8.0 Hz, 2 H), 7.82 (d, J = 8.0 Hz, 2 H) ppm. HRMS (ESI): Calculated for C36H44N4NaO10S4
[2M + Na]+ = 843.1832; found, 843.1832. When using 13 as a catalyst and following Procedure 3.2.2,
scalemic 8ba was obtained in 89.4% yield (8:1 diastereomer mixture).
(−)-4-Methyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-one, 9ba. Oxidation of 8ba obtained by catalyst
13 gave (−)-9ba (96:4 er) in 98% yield (58 mg, 0.14 mmol) according to Procedure 3.2.3. Colorless
solid, m.p. 156–160 ◦C (recrystallized from 1:2:7 dichloromethane/chloroform/hexanes). 1H-NMR
(CDCl3): δ = 0.76 (d, J = 7.0 Hz, 3H), 2.12–2.23 (m, 1H), 2.46 (s, 6H), 2.83–2.90 (m, 1H), 4.28–4.33 (m, 1H),
7.34–7.36 (m, 4H), 7.89 (d, J = 8.1 Hz, 2H), 7.89 (d, J = 8.1 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 15.3,
21.8, 34.7, 65.8, 127.0, 128.3, 128.7, 128.8, 129.6, 129.8, 130.1, 146.0, 146.2, 176.5 ppm. HRMS (ESI):
Calculated for C36H40N4NaO10S2 [2M + Na]+ = 839.1519; found, 839.1516. [α]25D = −64.7 (0.67, DCM).
Conditions for the HPLC analysis: Chiralpak® IA column, 90:10 hexane/2-propanol, 1 µL/min, 25 ◦C,
λ = 254 nm. tR (major enant.) = 33.6 min, tR (minor enant.) = 51.5 min.
4-Benzyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-ol, 8bb. The racemic compound was obtained as a
diastereomer mixture (>9:1 dr) in 85% yield (85 mg, 0.18 mmol) according to Procedure 3.2.1. Yellow
solid, m.p. 110–113 ◦C. 1H-NMR (CDCl3, major isomer): δ = 2.14–2.20 (m, 1H), 2.35–2.42 (m, 2H), 2.46
(s, 3H), 2.47 (s, 3H), 2.82–2.87 (m, 1H), 3.45–3.47 (br d, 1H, OH), 3.89–3.94 (m, 1H), 5.36–5.40 (m, 1H),
7.28–7.31 (m, 5H), 7.67 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 2H) ppm. HRMS (ESI): Calculated
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for C48H56N5O10S4 [2M + NH4]+ = 990.2805; found, 990.2805. When using 13 or 14 as catalysts and
following Procedure 3.2.2, scalemic 8bb was obtained in the same yield and diastereomeric ratio.
4-Benzyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-one, 9bb. Oxidation of 8bb according to Procedure
3.2.3 gave 9bb in 97% yield (58 mg, 0.12 mmol). Yellow solid, m.p. 156–160 ◦C. 1H-NMR (CDCl3):
δ = 2.01–2.07 (m, 1H), 2.45–2.47 (m, 1H), 2.47 (s, 3H), 2.48 (s, 3H), 2.90–2.95 (m, 1H), 2.98–3.01 (m, 1H),
4.05–4.011 (m, 1H), 6.81 (m, 1H), 7.20 (m, 3H), 7.34 (d, J = 6 Hz, 4H), 7.73 (d, J = 7.6 Hz, 2H), 7.86
(d, J = 7.6 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 21.79, 21.82, 34.7, 42.7, 54.0, 127.0, 128.3, 128.7,
128.8, 129.6, 129.8, 130.1, 131.2, 134.67, 134.73, 146.0, 146.2, 176.5 ppm. HRMS (ESI): Calculated for
C24H28N3NaO5S2 [M + NH4]+ = 502.1465; found, 502.1466. No satisfactory conditions for the chiral
HPLC analysis of this compound could be found.
4-Hexyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-ol, 8bc. The racemic compound was obtained as a
diastereomer mixture (10:1 dr) in 98% yield (97 mg, 0.20 mmol) according to Procedure 3.2.1. Yellow
solid, m.p. 78–80 ◦C. 1H-NMR (CDCl3, major isomer): δ = 0.87 (t, J = 7.0 Hz, 3H), 0.95–1.00 (m, 1H),
1.13–1.18 (m, 6H), 1.22–1.27 (m, 3H), 2.01–2.14 (m, 1H), 2.44 (s, 3H), 2.45 (s, 3H), 2.85–2.87 (m, 1H),
3.35–3.37 (br d, 1H, OH), 4.08–4.13 (m, 1H), 5.24–5.28 (m, 1H), 7.27–7.32 (m, 4H), 7.68 (d, J = 8.0 Hz,
2H), 7.81 (d, J = 8.0 Hz, 2H) ppm. HRMS (ESI): Calculated for C23H32N2NaO5S2 [M + Na]+ = 503.1642;
found, 503.1645. When using 13 as a catalyst and following Procedure 3.2.2, scalemic 8bc was obtained
in 93% yield (104 mg, 0.23 mmol; 10:1 dr).
(−)-4-Hexyl-1,2-bis-(4-toluenesulfonyl)-pyrazolidin-3-one, 9bc. Oxidation of 8bc (obtained by catalyst 13)
according to Procedure 3.2.3 gave (−)-9bc (78:22 er) in 98% yield (58 mg, 0.12 mmol). Colourless
solid, m.p. 160–164 ◦C. 1H-NMR (CDCl3): δ = 0.83–0.86 (m, 5H), 1.05–1.12 (m, 4H), 1.19–1.25 (m, 3H),
1.40–1.52 (m, 1H), 2.08–2.11 (m, 1H), 2.45 (s, 3H), 2.46 (s, 3H), 2.93–3.00 (m, 1H), 4.24–4.29 (m, 1H),
7.33–7.36 (m, 4H), 7.78 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H) ppm. 13C-NMR (CDCl3): δ = 13.9, 21.7,
21.8, 22.4, 26.2, 28.6, 28.7, 31.3, 41.0, 54.1, 128.7, 129.6, 129.8, 130.1, 131.3, 134.8, 145.9, 146.2, 177.5 ppm.
HRMS (ESI): Calculated for C23H30N2NaO5S2 [M + Na]+ = 501.1488; found, 501.1491. [α]25D = −8.0
(1.01, DCM). Conditions for the HPLC analysis: Chiralpak® IB column, 93:7 hexane/2-propanol,
1 µL/min, 25 ◦C, λ = 220 nm. tR (major enant.) = 21.5 min, tR (minor enant.) = 27.6 min.
Benzyl 5-hydroxy-4-methyl-isoxazolidine-2-carboxylate, 11a. The racemic compound was obtained as a
2:1 diastereomer mixture in 83% yield (102 mg, 0.43 mmol) according to Procedure 3.3.1. Colorless
oil. 1H-NMR (CDCl3, major isomer): δ = 1.09 (d, J = 7 Hz, 3H), 2.60–2.67 (m, 1H), 3.61–3.64 (m, 1H),
4.26–4.29 (m, 1H), 5.16 (br s, 2H), 5.34–5.35 (m, 1H), 7.32–7.35 (m, 5H) ppm. 1H-NMR (CDCl3, minor
isomer): δ = 1.13 (d, J = 7.0 Hz, 3H), 2.55–2.59 (m, 1H), 3.78–3.82 (m, 1H), 4.14–4.17 (m, 1H), 5.22 (br s,
2H), 5.55–5.56 (m, 1H), 7.37–7.39 (m, 5H) ppm. 13C-NMR (CDCl3): δ = 9.4, 14.7, 40.4, 44.1, 67.8, 68.1,
73.5, 74.9, 82.1, 88.0, 128.29, 128.34, 128.43, 128.46, 128.5, 128.6, 135.38, 135.44, 141.8, 155.3, 159.0 ppm.
When using 13 or 14 as catalysts and following Procedure 3.3.2, scalemic 11a was obtained in similar
yield and diastereomer ratio.
Benzyl 4-methyl-5-oxo-isoxazolidine-2-carboxylate, 12a. Oxidation of 11a gave 12a in 98% yield (50 mg,
0.22 mmol) according to Procedure 3.3.3. Colorless oil. 1H-NMR (CDCl3): δ = 1.29 (d, J = 6.8 Hz, 3H),
3.01–3.11 (m, 1H), 3.96–4.01 (m, 1H), 4.54–4.58 (m, 1H), 5.33 (br s, 2H), 7.33–7.45 (m, 5H) ppm.13C-NMR
(CDCl3): δ = 12.2, 39.4, 68.8, 73.9, 98.0, 128.54, 128.6, 134.5, 147.7, 169.9 ppm. HRMS (ESI): Calculated
for C12H14NO4 [M + H]+ = 236.0917; found, 236.0916. No satisfactory conditions could be found for
the chiral HPLC analysis of this compound.
Benzyl 4-benzyl-5-hydroxy-isoxazolidine-2-carboxylate, 11b. The racemic compound was obtained as a 3:1
diastereomer mixture in 79% yield (128 mg, 0.41 mmol) according to Procedure 3.3.1. Colorless oil.
1H-NMR (CDCl3, major isomer): δ = 2.74–2.78 (m, 2H), 3.02–3.06 (m, 1H), 3.57–3.61 (m, 1H), 3.77–3.80
(m, 1H), 4.19–4.23 (m, 1H), 5.25 (br s, 2H), 5.47–5.48 (m, 1H), 7.31–7.41 (m, 10H) ppm. 1H-NMR
(CDCl3, minor isomer): δ = 2.59–2.68 (m, 2H), 2.94–2.98 (m, 1H), 3.01–3.27 (m, 1H), 3.67–3.71 (m, 1H),
4.01–4.05 (m, 1H), 5.36 (br s, 2H), 5.56–5.57 (m, 1H), 7.13–7.30 (m, 10H) ppm. 13C-NMR (CDCl3):
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δ = 23.5, 31.2, 35.8, 48.0, 48.8, 51.0, 68.1, 71.9, 72.9, 81.3, 86.1, 97.2, 101.4, 126.5, 126.7, 128.1, 128.2, 128.4,
128.5, 128.6, 128.7, 135.5, 135.7, 138.2, 138.9, 155.2, 158.8 ppm.
Benzyl 4-benzyl-5-oxo-isoxazolidine-2-carboxylate, 12b. Oxidation of 11b gave 12b in 99% yield (68 mg,
0.22 mmol) according to Procedure 3.3.3. Colorless oil. 1H-NMR (CDCl3): δ = 2.78–2.84 (m, 1H),
3.24–3.28 (m, 2H), 4.07–4.11 (m, 1H), 4.35–4.39 (m, 1H), 5.33 (br s, 2H), 7.15–7.43 (m, 10H) ppm.13C-NMR
(CDCl3): δ = 30.7, 43.0, 65.7, 68.8, 123.9, 125.3, 125.4, 125.5, 125.7, 131.3, 134.0, 144.4, 165.4 ppm. HRMS
(ESI): Calculated for C18H21N2O4 [M + NH4]+ = 329.1496; found, 329.1494.
Benzyl 4-hexyl-5-hydroxy-isoxazolidine-2-carboxylate, 11c. The racemic compound was obtained as a 3:1
diastereomer mixture in 78% yield (120 mg, 0.39 mmol) according to Procedure 3.3.1. Colorless oil.
1H-NMR (CDCl3, major isomer): δ = 0.88 (d, J = 7.0 Hz, 3H), 1.28–1.31 (m, 9H), 1.34–1.38 (m, 1H),
2.45–2.55 (m, 2H), 3.62–3.66 (m, 1H), 4.26–4.28 (m, 1H), 5.22 (br s, 2H), 5.39–5.40 (m, 1H), 7.37–7.40
(m, 5H) ppm. 1H-NMR (CDCl3, minor isomer): δ = 0.87 (d, J = 7.0 Hz, 3H), 1.34–1.38 (m, 9H), 3.15–3.19
(m, 2H), 3.81–3.86 (m, 1H), 4.02–4.25 (m, 1H), 5.33 (br s, 2H), 5.39–5.40 (m, 1H), 7.32–7.36 (m, 5H) ppm.
When using 14 as a catalyst and following Procedure 3.3.2, scalemic 11c was obtained in 87% yield
(201 mg, 0.65 mmol) and in a 3:1 diastereomer ratio.
(−)-Benzyl 4-hexyl-5-oxo-isoxazolidine-2-carboxylate, 12c. Oxidation of 11c obtained with catalyst 14 gave
(−)-12c (57:43 er) in 87% yield (87 mg, 0.28 mmol) according to Procedure 3.3.3. Colorless oil. 1H-NMR
(CDCl3): δ = 0.88 (d, J = 7.0 Hz, 3H), 1.28–1.40 (m, 8H), 1.50–1.58 (m, 1H), 1.88–1.93 (m, 1H), 2.92–2.99
(m, 1H), 4.04–4.08 (m, 1H), 4.52–4.56 (m, 1H), 5.33 (br s, 2H), 7.33–7.45 (m, 5H) ppm. 13C-NMR (CDCl3):
δ = 14.0, 22.5, 27.0, 28.1, 29.0, 31.5, 44.5, 68.8, 72.6, 128.5, 128.6, 128.7, 134.6, 147.7, 169.5 ppm. HRMS
(ESI): Calculated for C34H46N2NaO8 [2M + Na]+ = 633.3146; found, 633.3148. [α]25D = −4.1 (0.41, DCM).
Conditions for the HPLC analysis: Chiralpak® IB column, 90:10 hexane/2-propanol, 1 µL/min, 25 ◦C,
λ = 254 nm. tR (minor enant.) = 13.6 min, tR (major enant.) = 16.3 min.
3.5. Methods for the Biological Activity Studies
3.5.1. Sample Preparation
Samples were provided as dry material, and were made to 10 mg/mL in DMSO solution and
stored at −20 ◦C. An aliquot of each sample was diluted to 320 µg/mL in water, and plated in 384-well
polypropylene plates. 5 µL was plated in duplicate into a 384-well non-binding surface plate for each
strain or cell type assayed against. Once cells were added this gave a final compound concentration
range of 32 µg/mL. The final DMSO concentration was 0.3%.
3.5.2. Antimicrobial Assay
Procedure
All bacteria were cultured in Cation-adjusted Müller Hinton broth (CAMBH) at 37 ◦C overnight.
A sample of each culture was then diluted 40-fold in fresh broth and incubated at 37 ◦C for 1.5–3 h.
The resulting mid-log phase cultures were diluted (CFU/mL measured by OD600), and then 45 µL was
added to each well of the compound containing plates, giving a cell density of 5 × 105 CFU/mL and
the nominated final compound concentration. All the plates were covered and incubated at 37 ◦C for
18 h without shaking.
Analysis
Inhibition of bacterial growth was determined measuring absorbance at 600 nm (OD600), using a
M1000 Pro monochromator plate reader (Tecan, Männedorf, Switzerland). The percentage of growth
inhibition was calculated for each well, using negative control (media only) and positive control
(bacteria without inhibitors) on the same plate as references. The significance of the inhibition values
was determined by Z-scores, calculated using the average and standard deviation of the sample wells
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(no controls) on the same plate. Samples with inhibition value above 80% and Z-Score above 2.5
(n = 2 on different plates) for either replicate were classed as actives.
3.5.3. Antifungal Assay
Procedure
Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose (YPD) agar at 30 ◦C.
A yeast suspension of 1 × 106 to 5 × 106 cells/mL (as determined by OD350) was prepared from
five colonies. These stock suspensions were diluted with Yeast Nitrogen Base (YNB) broth to a final
concentration of 2.5 × 103 CFU/mL. Then, 45 µL of the fungi suspension was added to each well
of the compound-containing plates, giving a final concentration of 32 µg/mL for the tested samples.
Plates were covered and incubated at 35 ◦C for 24 h without shaking.
Analysis
Growth inhibition of C. albicans was determined measuring absorbance at 530 nm (OD530), while
the growth inhibition of C. neoformans was determined measuring the difference in absorbance between
600 and 570 nm (OD600–570), after the addition of resazurin (0.001% final concentration) and incubation
at 35 ◦C for additional 2 h. The absorbance was measured using a Biotek Synergy HTX plate reader.
The percentage of growth inhibition was calculated for each well, using negative control (media only)
and positive control (fungi without inhibitors) on the same plate as references. The significance of the
inhibition values was determined by Z-scores, calculated using the average and standard deviation
of the sample wells (no controls) on the same plate. Samples with inhibition value above 80% and
Z-Score above 2.5 (n = 2 on different plates) for either replicate were classed as actives.
3.5.4. Antibiotic Standards Preparation and Quality Control
Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative
and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor standard
both for C. albicans and C. neoformans.
The antibiotics were provided in four concentrations, with two above and two below its MIC
value, and plated into the first 8 wells of column 23 of the 384-well NBS plates. The quality control
(QC) of the assays was determined by the antimicrobial controls and the Z’-factor (using positive and
negative controls). Each plate was deemed to fulfill the quality criteria (pass QC), if the Z’-factor was
above 0.4, and the antimicrobial standards showed full range of activity, with full growth inhibition at
their highest concentration, and no growth inhibition at their lowest concentration.
3.5.5. Materials
Both the compound preparation plate and the assay plates were purchased from Corning
(Corning, NY, USA). CAMHB from Bacto Laboratories (Mount Pritchard, Australia) was used as
growth media for bacteria; culture agar and growth media for fungi were purchased from Becton
Dickinson (Franklin Lakes, NJ, USA). Resazurin was provided by Sigma Aldrich (Sydney, Australia).
3.5.6. Microbial Strains
Escherichia coli ATCC 25922 (FDA control strain)
Klebsiella pneumoniae ATCC 700603 (MDR)
Acinetobacter baumannii ATCC 19606 (type strain)
Pseudomonas aeruginosa ATCC 27853 (Quality control strain)
Staphylococcus aureus ATCC 43300 (MRSA)
Candida albicans ATCC 90028 (CLSI reference)
Cryptococcus neoformans ATCC 208821 (H99—Type strain)
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4. Conclusions
The pyrrolidine-catalyzed reaction of the α-substituted enals methacrolein (7a), 2-benzylpropenal
(7b), and 2-(n-hexyl)propenal (7c) with the activated hydrazines 1-Boc-2-(4-nitrobenzenesulfonyl)
hydrazine (2a) and 1,2-bis(p-toluenesulfonyl)hydrazine (2b) takes place in very good yields
(83%–99.6%) in toluene at room temperature and in the presence of benzoic acid as a co-catalyst,
to afford the 4-substituted pyrazolidin-3-ols 8aa–8bc (generally as diastereomer mixtures); oxidation
of these compounds with PCC leads to the corresponding-4-substituted-3-pyrazolidinones 9aa–9bc in
essentially quantitative yields. In the same conditions α-substituted acroleins 7a–7c react smoothly
with N-Cbz-hydroxylamine 10 to afford the isoxazolidinols 11 in good yields (78%–83% isolated
yields) as diastereomer mixtures. Subsequent oxidation with PCC gives rise to the 4-substituted
isoxazolidin-5-ones 12a–12c. The use of chiral diarylprolinol trimethylsilyl ethers 13 and 14 as catalysts
allows the synthesis of several of these compounds in optically active form, in some cases with excellent
enantioselectivity (up to 96:4 er). The 4-substituted pyrazolidinols, pyrazolidinones, isoxazolidinols
and isoxazolidinones (both in racemic and when possible in enantiomerically enriched form) have
been submitted to a primary antimicrobial screening study (antibacterial and antifungal) by whole cell
growth inhibition assays. Antifungal activity has been found for the isoxazolidinones 12a and 12b,
and for isoxazolidinol 11c, and the 4-methyl-pyrazolidinol 8aa, both in racemic and in enantiomerically
enriched form, is highly active against Staphylococcus aureus.
Supplementary Materials: The following are available online at: http://www.mdpi.com/1420-3049/21/12/
1655/s1, NMR spectra and chiral HPLC traces for compounds 3, 5, 8aa–8bc, 9aa–9bc, 11a–11c and 12a–12c
(31 pages).
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